Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-2 adrenoreceptor (α2 adrenergic receptor) is a G protein-coupled receptor (GPCR) that primarily couples to the Gi class of heterotrimeric G-proteins. It mediates physiological responses to catecholamines, such as norepinephrine and epinephrine, in both the central and peripheral nervous systems. Activation leads to inhibition of adenylyl cyclase, decreased cAMP, and reduced neurotransmitter release. Subtypes include α2A, α2B, and α2C, with distinct localization and functions. Agonists like clonidine and dexmedetomidine are used for various therapeutic purposes, including hypertension management, sedation, and analgesia.
Activation of alpha-2 adrenoreceptors inhibits adenylyl cyclase via Gi proteins, reducing cyclic AMP levels and leading to hyperpolarization. This decreases calcium influx at nerve terminals and suppresses neurotransmitter release, particularly norepinephrine.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-2 Adrenoreceptor (α2 adrenergic receptor).